The FINANCIAL — Sanofi announced abstracts spanning the company’s innovative marketed and late-stage development compounds will be featured at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, Ill., June 1-5. Sanofi products are noted in more than 170 abstracts to be presented at the meeting.
According to Sanofi, this year’s meeting theme – Collaborating to Conquer Cancer – aligns with Sanofi Oncology’s approach to drug discovery and development through external partnerships that complement internal expertise. Diverse collaborations with leading scientists, academic institutions and other industry partners have brought forth numerous compounds to be highlighted in poster and oral presentations at the meeting, including investigational agents Zaltrap and the JAK2 inhibitor, SAR302503.
“The data to be presented at ASCO underscore the commitment of Sanofi Oncology to the patient and focus on innovative scientific discovery to develop cancer therapies that meet patient needs,” said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. “I thank the investigators and our partners for their strong collaboration in helping realize this progress.”
Discussion about this post